Abstract Library

#4648 Analysis of presentation and outcomes of mixed adenoneuroendocrine carcinoma (MANEC) – A single centre experience

Introduction: Mixed adenoneuroendocrine carcinoma (MANEC) is a rare neoplasm characterised by the coexistence of both adenocarcinoma and neuroendocrine carcinoma components. Due to its rarity, limited data exist regarding its clinical presentation, treatment strategies, and outcomes. This study provides an analysis of MANEC cases from a single centre, providing insights into its clinical features, diagnostic challenges, treatment strategies, and prognosis.

Conference:

Presenting Author: Khosla D

Authors: Khosla D, Kapoor R, Mehta A, Gupta R, Singh H,

Keywords: MANEC, mixed adenoneuroendocrine carcinoma, treatment,

#4643 Characterisation of patients with progressive digestive NET during PRRT (LUTA-CHEC): A multicentre study from the Groupe des Tumeurs Endocrines

Introduction: PRRT with 177Lu-DOTATATE is a major treatment for metastatic digestive NETs. Most patients have prolonged progression-free survival, but around 20% experience early progression.

Conference:

Presenting Author: Haissaguerre M

Authors: Haissaguerre M, Hadoux J, Tlili G, Deshayes E, Lacombe M,

Keywords: GEP-NET, PRRT, early tumour progression,

#4634 Management of hypercalcaemia of malignancy in neuroendocrine tumour patients – A case series

Introduction: Hypercalcaemia of malignancy (HM) rarely coexists with neuroendocrine tumours (NET). There are no precise guidelines for management of hypercalcaemia in NET.

Conference:

Presenting Author:

Authors: Klepinowska M, Sagan K, Brzeska A, Andrysiak-Mamos E, Kiedrowicz B,

Keywords: hypercalcaemia of malignancy, neuroendocrine tumour, pancreatic neuroendocrine tumour, hypercalcaemia,

#4625 Efficacy and safety of capecitabine-temozolomide (CAPTEM) regimen in patients with neuroendocrine neoplasms – A systematic review and experience from NETwerk, a Belgian ENETS Center of Excellence

Introduction: Current treatment guidelines remain inconclusive due to scarcity of data regarding the optimal systemic treatment for metastatic gastroenteropancreatic (GEP) neuroendocrine tumours (NET) grade 3 and aggressive GEP-NET grade 2. Similarly, for metastatic pulmonary typical (TC) and atypical carcinoids (AC), the indication for chemotherapy is unclear. Recent evidence highlights a promising role for CAPTEM, combining temozolomide (TEM) with capecitabine (CAP), showing encouraging antitumoural activity and safety profiles for these indications.

Conference:

Presenting Author: Chhajlani S

Authors: Chhajlani S, Lambrechts C, Islam O, de Weerdt C, Verbruggen L,

Keywords: capecitabine, temozolomide, CAPTEM, GEP-NET, pulmonary NEN, safety, efficacy, systematic review,

#4610 The last 10 years – Single centre experience of gastrointestinal NEN

Introduction: Neuroendocrine neoplasms (NEN) are rare and heterogeneous, comprising 2% of all malignancies, with progressively increasing incidence. Most arise sporadically and the most frequent primary sites are gastrointestinal and lung.

Conference:

Presenting Author:

Authors: Corrêa Figueira C, Alves H, Bento A, Oliveira M, Garrido R,

Keywords: Neuroendocrine neoplasm, Gastrointestinal neuroendocrine tumour, Multidisciplinary team meeting, Retrospective, Single centre,